Paclitaxel

Paclitaxel induces apoptosis in leukemia cells through a JNK activation-dependent pathway

Z. G. Peng, Liu, D. C., Yao, Y. B., Feng, X. L., Huang, X., Tang, Y. L., Yang, J., Wang, X. X., Peng, Z. G., Liu, D. C., Yao, Y. B., Feng, X. L., Huang, X., Tang, Y. L., Yang, J., and Wang, X. X., Paclitaxel induces apoptosis in leukemia cells through a JNK activation-dependent pathway, vol. 15, p. -, 2016.

Paclitaxel (PTX) is a mitotic inhibitor widely used in chemotherapy for many types of cancers, including solid tumors and hematological malignancies. However, the molecular basis of the anti-proliferation activity of PTX is not fully understood. In this paper, we focused on the role of c-Jun N-terminal kinase (JNK) pathways in PTX-induced apoptosis and proliferation inhibition.

Effect of lipoic acid combined with paclitaxel on breast cancer cells

B. J. Li, Hao, X. Y., Ren, G. H., and Gong, Y., Effect of lipoic acid combined with paclitaxel on breast cancer cells, vol. 14, pp. 17934-17940, 2015.

Breast cancer is the most common gynecologic tumor globally that threatens women’s health. Lipoic acid is a type of antioxidant that can alleviate oxidative stress damage. Studies showed that lipoic acid could inhibit the proliferation of tumor cells in cervical cancer and colon cancer. This paper intends to explore the combined effect of lipoic acid and paclitaxel on breast cancer cells. Breast cancer MCF-7 cells were divided into four groups: control group, lipoic acid group, paclitaxel group, and a combination group.

Subscribe to Paclitaxel